Is imatinib (Gleevec) included in the scope of medical insurance reimbursement?

Imatinib, also known as Gleevec, is a classic tyrosine kinase inhibitor mainly used to treat malignant tumors such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). As one of the world's first successful targeted therapy drugs, imatinib has long been approved for marketing in China and has played an important role in clinical application in China. With the continuous optimization of national medical insurance policies, this drug has been officially included in the scope of medical insurance reimbursement, greatly reducing the financial burden on patients.

Currently, in China, the common specification of imatinib is100mg*60 tablets, and its price after medical insurance is relatively affordable, about six to seven hundred yuan. Since it has been included in the medical insurance catalog, patients can purchase it at most public hospitals or medical insurance designated pharmacies and enjoy a certain proportion of medical insurance reimbursement, provided they have a doctor's prescription. However, since medical insurance policies vary slightly from place to place, patients are advised to consult with the local hospital pharmacy or medical insurance bureau for specific reimbursement ratios and payment amounts.

In addition to the domestic market, imatinib generics produced in India have also attracted the attention of some patients. The specifications of Indian generic drugs are usually 100mg*120 tablets, and the price is about three to four hundred yuan, which is slightly lower than the price after domestic medical insurance. However, although the price is cheaper, Indian generic drugs belong to overseas channels and are usually not covered by domestic medical insurance. They also cannot enjoy medication guidance from formal medical institutions. Patients need to ensure drug safety and efficacy through formal channels.

Overall, imatinib is more cost-effective after being reimbursed by domestic medical insurance, and is more reliable in terms of drug quality and medication guarantee. For most patients, obtaining a prescription from a hospital and using imatinib within the scope of medical insurance not only provides guaranteed treatment, but also benefits from national policies, making it a more reliable and long-term sustainable treatment method.

Reference materials:https://www.gleevec.com/